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Obese animals and humans demonstrate higher sensitivity to pain stimuli. Among the endogenous factors prompting obesity, the
intestinal microbiota has been proposed to influence responsiveness to pain.(e beneficial effects of probiotics on obesity are well
documented, whereas data on their analgesic efficacy is minimal.(e protective effect of probiotics on nociception in diet-induced
obese male mice has been previously demonstrated, but the sex differences in pain sensitivity and analgesic response do not allow
for the generalization of these findings to the female gender. Hence, this study aimed at investigating the potential effects of oral
probiotic supplementation on mechanical pain thresholds in female diet-induced obese mice compared with controls. (irty-two
adult female mice (N � 32) were randomly divided into two groups receiving standard (normal-weight group; NW) or high-fat
diet (diet-induced obesity; DIO). All rats received a single daily dose (1× 109 CFU) of probiotics (Lactobacillus rhamnosus PB01,
DSM14870) for four weeks by gavage. Mechanical pain thresholds were recorded by an electronic von Frey device at baseline, at
the end of weeks 2, 4, 6, and 8 in both DIO and NW groups with and without consumption of probiotics. Blood samples were
obtained for the measurement of lipid profile and reproductive hormone levels. Bodyweight was considerably lower (P< 0.001) in
groups supplied with probiotics than groups without probiotics. Pressure pain threshold values showed a significant (P< 0.001)
increase (reduced pain sensitivity) following probiotic supplementation, proposing a modulatory effect of probiotics on me-
chanical sensory circuits and mechanical sensitivity, which might be a direct consequence of weight loss or an indirect result of the
probiotics’ anti-inflammatory properties. Understanding the precise underlying mechanism for the effect of probiotics on weight
loss and mechanical pain sensitivity seen in this study warrants further investigation.
1. Introduction
Pain is a complex, multidimensional perception that varies in
quality, strength, duration, location, and unpleasantness. (e
strength and unpleasantness of pain are neither simply nor
directly related to the nature and extent of tissue damage [1].
Physiological pain is a warning mechanism that protects an
organismby inducing awithdrawal response to harmful stimuli,
while chronic pain indicates medical pathogenesis that needs
treatment, which is often challenging [2]. Neurotransmitters,
immune cells, and hormones have been demonstrated to
contribute to the pathogenesis of chronic pain [3].
Biological factors, including gender and genetics, have
been shown to alter pain perception both in humans and
animals [4]. (e influence of diet on pain perception is also
well known [5]. It has been suggested that adiposity is
strongly associated with pain, which is more prevalent in
obese than nonobese individuals [6]. Obesity alters adipose
tissue metabolic and endocrine functions, which have been
previously reported to influence pain perception [6]. (e
adipose tissue generates proinflammatory cytokines such as
interleukin 6 (IL-6), tumor necrosis factor α (TNF-α), and
leptin, in addition to C-reactive protein (CRP) which is
released from the liver in response to IL-6 [7].
Studying the association between pain and obesity in
patients is somewhat challenging; this is mainly due to the
multifaceted and subjective nature of pain, the complexity of
obesity, and its related confounding factors [8]. Mouse
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models of obesity, in which responsiveness to controlled
pain stimuli can be assessed, provide a control platform to
study coexisting conditions of pain and obesity and the
effects of modulating strategies, such as dietary factors. (e
gut microbiota composition has been implicated in obesity
development [9]. (is composition can be influenced by
many factors such as medicine, disease, host genetics, and
diet, which is considered the major contributor [10]. Many
studies have indicated that diet can alter the ratio of two
critical bacterial divisions known as Bacteroidetes and
Firmicutes. (ese studies have reported exposure to a high-
fat diet to decrease Bacteroidetes and increase Firmicutes
phyla levels [11].
Furthermore, losing weight by following a low-calorie
diet may increase the abundance of Bacteroidetes in obese
people [12]. (ereby, modulation of the gut microbiota
using probiotic supplements may offer a novel tool in obesity
management. Probiotics have shown antiobesity properties,
anti-inflammatory/antioxidant properties, and the ability to
modify energy homeostasis and enhance gut and systemic
immune function [13]. On the other hand, probiotics can act
on the intestinal tract and protect it from other microbes and
pathogens either by competing with them for receptors and
binding sites, thus preventing the microbes from adhering to
the intestinal mucus [14], by strengthening the gut epithelial
barrier [15], or by producing antimicrobial agents to sup-
press another microorganisms’ growth [16]. Probiotics have
also shown a beneficial effect on gastrointestinal-related
pain. For example, a study on irritable bowel syndrome
patients treated with L. plantarum showed decreased pain
sensitivity in these patients [17]. However, studies focusing
on other types of pain are lacking.
A preclinical study demonstrated that diet-induced
obese (DIO) male mice receiving oral probiotic supple-
mentation demonstrated lower sensitivity to pressure pain
than DIO male mice without probiotic supplementation [4].
However, a growing body of evidence confirms sex differ-
ences in pain sensitivity and analgesic response, observed in
acute and chronic clinical pain and experimental models
[18]. Overall, females have higher pain sensitivity to several
pain stimuli (e.g., mechanical, thermal, chemical, and
electrical) and a higher prevalence of chronic pain condi-
tions such as fibromyalgia, temporomandibular disorders, or
headaches [19].
Females are also reported to have a higher prevalence of
obesity [20]. (us, the results of the above-mentioned study
on male mice [4] cannot be generalized to the female.
(ere are limited studies on the underlying mechanisms
of pain-obesity focusing on the female population, while the
effects of dietary components and supplementation with
probiotics on pain sensitivity in female mouse models have
not yet been investigated.
(erefore, this study aimed to assess the impact of oral
administration of Lactobacillus rhamnosus PB01 (DSM
14870) on pressure pain thresholds in normal-weight and
diet-induced obese female mouse models to address if
probiotic supplements can potentially overcome the dele-
terious effects of obesity and reduce pain sensitivity. (e
results of this study would also provide evidence on whether
consumption of probiotics can modulate pain, obesity, or
both and if hormonal changes would be present in response
to the supplementation.
2. Materials and Methods
All experiments were carried out following the Guidelines
for Animal Experimentation and Approval of “(e Danish
Animal Experiments Inspectorate” (study case number:
2016−15−0201−00867). (is study was performed on thirty-
two adult female C57BL/6NTac mice (Taconic, Denmark),
housed in a room with 60% humidity, 22°C to 24°C tem-
perature, and 12 h dark-light cycles (light on from 0800 to
2000 h). Mice were allowed two weeks of adaptation and free
access to their respective diets and tap water ad libitum
during the study period.
2.1. Study Design. (e study consisted of two phases.
Phase I: following the adaptation period, the estrus cycles
were synchronized before randomly dividing the mice into
two groups to be fed for four weeks on a high-fat (60%)
Research Rodent Diet (D12492, Research Diets, Inc., USA)
to create the diet-induced obesity (DIO) model or a standard
diet (normal-weight group; NW) as the control (lean) group.
Phase II: after four weeks on the respective diets, each
group was further divided into two subgroups. (e four new
groups continued with the previous diet with or without
probiotic supplements for four weeks, creating the following
four diet groups.
Group 1: lean group on normal diet (ND)
Group 2: lean group on normal diet and probiotic
supplement (NDPR)
Group 3: DIO group on fat diet (FD)
Group 4: DIO on fat diet and probiotic supplement
(FDPR)
2.2. Estrus Cycle Synchronization. After the adaptation
phase, to synchronize the estrous cycles, the mice were given
a single intraperitoneal injection of 0.5 μg of coprostanol
(CC-13104; Cayman Chemical, USA) and 3 μg of subcuta-
neous progesterone (Cayman Chemical, USA), followed by
0.5 μg of coprostanol three days later [21]. During weeks 3-4
and 7-8 of the study, animals were checked for the estrus
cycle by examining vaginal cytology and allowed at least one
regular estrous cycle (4-5 days in length) before blood
collection during the diestrus phase. (e mice were put on
the research diet (according to the diet groups explained
earlier) one day after the estrus synchronization.
2.3. BMI Measurements. BMI of the mice was calculated
once every two weeks by measuring the weight and the
length of the animals from the tip of the nose to the end of
the tail.
2.4. Probiotics. Lactobacillus rhamnosus PB01, DSM 14870,
was provided as a lyophilized powder by Deerland Probiotics
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and Enzymes (Hundested, Denmark). Aliquots providing
1× 109 CFU per mouse were prepared (based on the man-
ufacturer’s guidelines) and stored at −20°C until use. (e
prepared probiotic aliquots were diluted with normal saline
at room temperature shortly before use (0.25ml per mouse)
and given to the NDPR and FDPR groups orally by a gavage
needle. ND and FD received normal saline without pro-
biotics. (is process was repeated once daily during phase II
(second 4 weeks) of the study.
2.5. Pressure Pain6reshold. Pressure pain threshold (PPT)
is defined as the minimum force applied, which induces
pain. (is measure has proven to be commonly useful in
evaluating multiple clinical pain states [22, 23]. Rodent
withdrawal reflex to pressure application upon the sensation
of pain is interpreted as similar to PPT assessment in
humans. In this study, mechanical pressure was applied to
the animal paw using the electronic Von Frey device (Bioseb,
France), and the pressure at which the paw withdrawal
happened was recorded. Mechanical sensitivities reflected
on PPT values were obtained every two weeks to estimate
nociception levels concerning obesity and probiotics ad-
ministration. Faster withdrawal with lower PPT values was
considered a higher sensitivity to mechanical stimuli.
2.6. Blood Serum Collection and ELISA Tests. Blood samples
were collected at the beginning of the study (baseline, after
synchronization), and every two weeks throughout the study
(at the end of weeks 2, 4, 6, and 8) from the facial vein of
conscious mice [24].
Blood serum was immediately collected by centrifuga-
tion (500 g for 10min at 4°C) and stored at −20°C until the
assessment of blood lipid profiles (total cholesterol (TC),
high-density lipoprotein (HDL), and low/very low-density
lipoprotein (LDL/VLDL)) using a commercially available
Elisa assay kit (ab65390, Abcam, United Kingdom),
according to the manufacturer’s directions. Blood serum
FSH, LH, testosterone, and leptin levels were also measured
using commercially available ELISA kits (MyBioSource,
USA; Cat. No: MBS703380, MBS041300, MBS7606180, and
MBS2885529, resp.) according to the manufacturer’s
directions.
2.7. Statistical Analysis. (e results have been presented as
means± standard deviation (SD) unless stated otherwise.
(e Shapiro–Wilk test was used to confirm the normal
distribution of the data. (e repeated measures analysis of
variance (ANOVA) was used to compare differences in pain
sensitivity, weight, lipid profiles, and hormone levels be-
tween groups. Tukey’s multiple comparison tests were used
for pairwise comparison of the hormone levels between the
groups. GraphPad Prism version 8.0.0 (224) was used to
perform the statistical analysis and P< 0.05 was considered
significant.
3. Results
3.1. 6e Effect of Probiotic Supplementation on Total Body
Weight. As illustrated in Figure 1, all groups demonstrated
weight gain during phase I (the first four weeks). (is in-
crease was significantly higher in the FD compared to the
ND group (P< 0.0001).
During phase II, the FD and ND groups maintained a
rising trend, whereas the FDPR and NDPR groups which
received Lactobacillus rhamnosus (PB01, DSM 14870)
showed a decrease in weight gain. At the end of the study, the
FDPR and NDPR groups presented a significantly lower
weight than the FD and ND groups, respectively (P< 0.001).
At the end of week 8, the FD group demonstrated a sig-
nificantly higher weight compared to the ND group
(P< 0.001), while the NDPR group demonstrated a signif-
icantly lower weight compared to the ND group (P< 0.001).
3.2. 6e Effect of Probiotic Supplementation on Pressure Pain
6reshold. Figure 2 illustrates the mean PPT values in the
different groups throughout the study. From weeks 0 to 4
(phase I), mice in both ND and FD groups without pro-
biotics supplementation demonstrated gradually lower PPT
values (higher pain sensitivity). From weeks 4 to 8 (during
phase II), the ND and FD groups continued lowering values
in PPT (higher pain sensitivity), with a larger decrease in FD
compared to ND (P< 0.001).
From weeks 4 to week 6, the NDPR group demonstrated
a slight increase in PPT (less sensitivity), followed by a
sudden significant increase from week 6 to week 8. Mice on
the fat diet with probiotic supplementation (FDPR) showed
an increase in PPT from week 4 to week 6 (less sensitivity)
(P< 0.001), continuing to significantly higher values com-
pared to NDPR at week 8 (P< 0.001).
3.3. 6e Effect of Probiotic Supplementation on Lipid Profiles
(Total Cholesterol, LDL/VLDL, HDL). (e lipid profiles
(total cholesterol, LDL/VLDL, and HDL levels) in mice of
the different groups (ND, NDPR, FD, and FDPR) at the end
of the study are illustrated in Table 1.
Total cholesterol showed significantly higher levels in the
FD group compared to ND at the end of the study (week 8;
p< 0.05). LDL/VLDL and HDL also showed higher ten-
dency levels in the FD group compared to ND at the end of
the study.
ND and FD groups also demonstrated higher tendency
levels of TC compared to NDPR and FDPR, respectively.
LDL levels showed a lower trend in FDPR than FD, andHDL
levels demonstrated a lower tendency in NDPR than ND.
3.4. 6e Effect of Probiotic Supplementation on Sex Hormone
Levels (Testosterone-FSH-LH). (e blood testosterone, FSH,
and LH levels in different groups of mice (ND, NDPR, FD,
and FDPR) at the end of the study are illustrated in Table 2.
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NDPR and FDPR demonstrated higher testosterone levels
than ND and FD groups, respectively, at the end of the study;
however, the difference remained insignificant.(ere was no
significant difference between ND and FD groups during
phase I (from baseline to week 4). LH concentrations were
similar among ND, FD, and NDPR. (e FDPR group had
lower LH levels than the FD group; however, the difference
remained insignificant.
FSH concentrations were significantly higher in the
NDPR group compared to ND (p< 0.05). However, there
was no significant difference when comparing FDPR to FD
and FD to ND, although a trend was observed.
3.5. 6e Effect of Probiotic Supplementation on Leptin Levels.
(e effect of probiotic supplementation on leptin levels is
illustrated in Table 2. Leptin concentrations showed
significantly (P< 0.001) higher levels in the FD group than
the ND group and significantly higher levels in the FDPR
group than the NDPR group.
Leptin concentrations were higher in the ND group than
the NDPR group and lower in the FD group than the FDPR
group with no significant difference.
3.6. Figures, Tables, and Schemes. Estimated marginal means
of weight and pressure pain threshold are shown in Figures 1
and 2. Mean (±standard deviation) concentration of serum
lipid profiles and testosterone, LH, and FSH levels are
provided in Tables 1 and 2.
4. Discussion
4.1. Probiotic Supplementation and BodyWeight. (e results
of this study showed that probiotics could influence body
weight and reduce it. During phase I (before receiving
probiotics, baseline to week 4), all groups demonstrated
weight gain, whereas, during phase II (weeks 4–8), groups
that received probiotics (NDPR, FDPR) demonstrated
weight loss, whereas groups without probiotics’ consump-
tion (ND, FD) continued gaining weight until the end of the
study. (ese results align with a previous study demon-
strating the weight loss effects of probiotics in humans with
similar probiotic strains [25]. Lactobacillus rhamnosus
GGMCC reviewed in another article also demonstrated a
positive effect on weight loss in animals and humans [26].
(e possible underlying mechanisms of action of pro-
biotics on body weight have been described in several
studies. One study described the ability of the probiotic
(Lactobacillus rhamnosus GG (LGG)) to reduce gaining
weight inmice fed with a high-fat diet by regulating lipid and
glucose metabolism [27]. It was reported that LGG sensitizes
insulin action by enhancing adiponectin production in white
adipose tissue, AMP-activated protein kinase (AMPK) ac-
tivation, and increasing the expressions of GLUT4 and lipid
oxidative genes in adipose tissue [27]. Lactobacillus rham-
nosus PL60 has shown a significant reduction in white
adipose tissue by producing conjugated linoleic acid in mice
fed with diet-induced obesity [28]. Lactobacillus Plantarum
FH185 is suggested to potentially reduce adipocyte size by
preventing adipocyte differentiation and inhibiting lipase
activity [29], hence demonstrating antiobesity properties.
Dardmeh et al. previously demonstrated that male mice
on a high-fat diet supplemented with Lactobacillus rham-
nosus PB01 (DSM 14870) maintained a stable weight, while
the same diet without probiotic supplementation led to a
massive weight gain [4, 30]. (is study’s results combined
with those previously reported by Dardmeh et al. [4]
demonstrated that probiotics affect weight sex indepen-
dently, possibly indicating that hormonal levels might not be
playing a role as prominent as other proposed mechanisms
of action for the probiotics’ weight-management properties.
(e amount of consumed food and type and quantity of
faeces among different groups was not considered objec-
tively in this study. Comparative assessment of food con-






















Figure 1: Estimated marginal means of weight in mice on normal
diet (ND), fat diet (FD), normal diet with probiotic supplemen-
tation (NDPR), and fat diet with probiotic supplementation
(FDPR) at weeks 0 (baseline), 2, 4, 6, and 8 of the study. Asterisks































Figure 2: Estimated marginal means of pressure pain threshold
(PPT) in mice on normal diet (ND), fat diet (FD), normal diet with
probiotic supplementation (NDPR), and fat diet with probiotic
supplementation (FDPR) at weeks 0 (baseline), 2, 4, 6, and 8 of the
study. Asterisks mark pairwise significance (P> 0.05).
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community analysis (16 s) of the gut microbiota in the
different groups by future studies, could provide an insight
into the underlying mechanism of the weight- and pain-
reducing effect of the probiotics.
4.2. Probiotics Supplementation and Pressure Pain6reshold.
Our results showed a higher pain sensitivity (reflected by
lower PPT values) in the FD than the ND group, which was
not significant, possibly due to the small sample size or
variations in the withdrawal measurement method. Nev-
ertheless, these results support the findings of several pre-
vious clinical studies, where the presence of pain complaints
showed to be more common in people with high BMI
compared to people with normal or low BMI [31–33].
Furthermore, obese adults and children are reported to
exhibit more pain complaints [34, 35]. However, there is still
some controversy in the literature. A study carried out by
Zahorska-Markiewicz et al. demonstrated that weight-re-
ducing treatment did not change the pain sensitivity in obese
women [36]. Moreover, obese rats and obese people are less
sensitive to pain stimuli than nonobese controls [37].
Tashani et al. conducted a study to investigate the re-
lation between the percentage and distribution of fat with
pain sensitivity response, reporting that the body site and the
percentage of subcutaneous fat might affect the pain re-
sponse to different types and intensities of stimuli. Fur-
thermore, they found that obese individuals were more
sensitive than nonobese people in response to pressure pain,
but not thermal pain [38].
Biomechanical factors and chemical mediators have
been considered as major underlying factors of the obesity-
pain association. High weight in obese individuals increases
the pressure on joints and results in defective structural
changes [39]. Furthermore, since adipocytes release proin-
flammatory markers (TNF-a, IL-6, and CRP) [40], obesity
may dysregulate the inflammatory markers and potentiate
the inflammatory response, which could lead to higher pain
sensitivity [7]. Ianniti et al. found that obese mice exhibited
more significant peripheral inflammation than lean mice
using carrageenan injection in the paw [41].
Our results also found that oral probiotics supplemen-
tation increased PPT values (lower mechanical pain sensi-
tivity). (is result agrees with previous studies, showing
increased PPT in male mice supplemented with probiotics
than groups without probiotics consumption [4].
Mechanisms underlying the reduction of pain sensitivity
following the administration of probiotics are not well in-
vestigated. A few studies have suggested that probiotic
strains display anti-inflammatory effects by downregulating
the production of inflammatory cytokines, thus controlling
pain [42]. A study performed by Abdelouhab et al. inves-
tigated the anti-inflammatory effect of “Ultrabiotique®” (a
probiotic) in ulcerative colitis (UC) treatment. Oral ad-
ministration of “Ultrabiotique®” decreased nitric oxide
levels, which usually rise in UC disease, which could confirm
the anti-inflammatory properties of probiotics [43]. Further
investigation to point out the precise mechanism is
warranted.
4.3. Probiotic Supplementation and Serum Lipid Profile (Total
Cholesterol, LDL/VLDL, HDL). Total cholesterol levels were
significantly higher in the FD group compared to ND. Some
previous studies have also reported that people with in-
creased BMIs showed higher serum total cholesterol than
normal-weight individuals [20, 44].
Probiotics supplements demonstrated a trend towards
reduced total cholesterol in both ND and FD groups and a
tendency towards reduced LDL/VLDL in the FD group,
which are in line with the direction of the findings in some
previous studies [4, 45]. It is possible that the dose or
Table 1: Mean (±standard deviation) concentration of serum lipid profiles in mice on normal (ND), high-fat diet (FD), normal diet with
probiotics (NDPR), or fat diet with probiotics (FDPR) at the end of the study (week 8). Similar letters demonstrate significant between-
group differences (P< 0.05).
Serum lipid profile
Group
ND NDPR FD FDPR
LDL/VLDL (μg/μl) 47.05± 11.76 52.45± 9.04 58.18± 16.73 55.06± 15.73
Total cholesterol (μg/μl) 76.88± 6.72a 76.72± 8.09 90.82± 5.62a 87.33± 6.393
HDL (μg/μl) 29.83± 12.64 24.27± 4.85 32.64± 17.64 32.27± 15.4
Table 2: Mean (±standard deviation) concentration values of testosterone, LH, and FSH levels in mice on normal (ND), high-fat diet (FD),
normal diet with probiotics (NDPR), or fat diet with probiotics (FDPR) at the end of the study (week 8). Similar letters demonstrate
significant between-group differences (P< 0.05).
Hormone
Group
ND NDPR FD FDPR
Testosterone (ng/dl) 10.25± 3.59 13.35± 4.51 10.27± 2.77 13.04± 3.8
LH (mIU/ml) 5.32± 0.74 5.26± 0.62 5.22± 0.69 5.02± 1.04
FSH (mIU/ml) 29.49± 9.41a 40.84± 3.81a 37.94± 3.68 44.94± 6.49
Leptin (ng/ml) 1.15± 0.2b 1.09± 0.08 2.099± 0.21b 2.20± 0.15
Pain Research and Management 5
duration of probiotic supplementation can influence the
outcome. Combinations of different strains of probiotics can
also be a choice.
(e study implemented by Guo et al. showed that a diet
rich in probiotics decreased TC and LDL concentrations in
individuals with high and normal cholesterol levels (Guo
et al., 2011).
A recent study suggested that probiotics have beneficial
effects on bile salt hydrolase (BSH) activity, which plays a
role in lipase action. Higher lipase activity accelerates the
breakdown of fat, thus decreasing body weight and plasma
cholesterol levels [46].
4.4. Probiotic Supplementation and Sex Hormone Levels
(Testosterone-FSH-LH). No significant difference was ob-
served in testosterone concentrations between ND and FD
groups in this study; however, the observed trends towards
higher levels of testosterone in the NDPR and FDPR
compared to ND and FD groups are in line with the findings
of a previous study where another strain of Lactobacillus
(L. reuteri) significantly increased testosterone concentra-
tion in mice regardless of the type of the diet [47, 48]. It has
to be noted that the different genders, supplementation
periods, doses, and strains of probiotics used in different
studies make comparisons between studies rather compli-
cated and challenging.
In groups without probiotic supplementation, FSH
showed a tendency towards higher levels in the FD com-
pared to the ND group. In the probiotic supplemented
groups, the lean mice showed a significant increase in FSH
levels, with a similar trend observed in the diet-induced
obese mice. Similar previous studies have also described an
increase in FSH due to probiotic supplementation [49].
(e increase in testosterone and FSH levels following
probiotics supplementationmay be explained by the relation
between obesity and testosterone, in which obesity decreases
testosterone levels. Weight loss can also decrease the
proinflammatory cytokines and CRP, suppressing their ef-
fect on the hypothalamic-pituitary axis (HPA), followed by
negative feedback increasing GnRH secretion and testos-
terone levels [50]. Lack of change in LH between the groups
could have been due to the estrous cycle synchronization,
making it challenging to see small changes in hormone levels
[51].
4.5. Probiotic Supplementation Effects on Leptin Levels.
Leptin is known to increase in people with obesity as it is
produced by adipose tissue, and the circulating concen-
tration of leptin is positively affected by body fat stores [52].
(e FDPR group demonstrated a tendency towards higher
levels of leptin compared to the FD group. (e increased
leptin levels send signals to the hypothalamic receptors to
inhibit appetite and stimulate metabolic rate and thermo-
genesis [53]. (e normal-diet group with probiotic sup-
plementation (NDPR) demonstrated lower leptin levels than
the ND group, although not significantly. (e decreased
concentrations of leptin correlate with the lower weight of
mice in the NDPR group.
5. Conclusions
Overall, this study provided evidence that Lactobacillus
rhamnosus (PB01, DSM 14870) probiotic supplementation
reduces weight and pain sensitivity in a female diet-induced
obesity mouse model, although the underlying mechanisms
remain to be investigated. (is study, combined with pre-
vious reports, indicates that the effect of probiotics on weight
is sex-independent, suggesting that hormonal levels might
not play a prominent role in the weight-management pain-
sensitivity lowering properties of probiotics. Regardless of
the underlying mechanism, Lactobacillus rhamnosus (PB01,
DSM 14870) supplementation can be proposed as a can-
didate for an innovative weight and pain management
strategy in both obese or normal-weight females.
Translation of this result to humans may lead to a novel
therapeutic approach to pain management of obese or
normal-weight individuals in the future.
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[45] R. Salaj, J. Štofilová, A. Šoltesová et al., “(e effects of two
Lactobacillus plantarum strains on rat lipid metabolism re-
ceiving a high fat diet,”6e Scientific World Journal, vol. 2013,
Article ID 135142, 7 pages, 2013.
[46] M. He and B. Shi, “Gut microbiota as a potential target of
metabolic syndrome: the role of probiotics and prebiotics,”
Cell & Bioscience, vol. 7, no. 1, p. 54, 2017.
[47] T. Levkovich, T. Poutahidis, C. Smillie et al., “Probiotic
bacteria induce a “glow of health”” PLoS One, vol. 8, no. 1,
Article ID e53867, 2013.
[48] T. Poutahidis, A. Springer, T. Levkovich et al., “Probiotic
microbes sustain youthful serum testosterone levels and
testicular size in aging mice,” PLoS One, vol. 9, no. 1, Article
ID e84877, 2014.
[49] K. H. Sultan and S. Y. A. Rahman, “Effect of probiotic on some
physiological parameters in broiler breeders,” International
Journal of Poultry Science, vol. 10, no. 8, pp. 626–628, 2011.
[50] D. M. Kelly and T. H. Jones, “Testosterone and obesity,”
Obesity Reviews, vol. 16, no. 7, pp. 581–606, 2015.
[51] B. G. Reed and B. R. Carr,6eNormalMenstrual Cycle and the
Control of Ovulation, MDText.com, Inc., Dartmouth, MA,
USA, 2000.
[52] M. Y. Al Maskari and A. A. Alnaqdy, “Correlation between
serum leptin levels, body mass index and obesity in Omanis,”
Sultan Qaboos University Medical Journal, vol. 6, pp. 27–31,
2006.
[53] N. Ekmen, A. Helvaci, M. Gunaldi, H. Sasani, and
S. T. Yildirmak, “Leptin as an important link between obesity
and cardiovascular risk factors in men with acute myocardial
infarction,” Indian Heart Journal, vol. 68, no. 2, pp. 132–137,
2016.
8 Pain Research and Management
